分组1 - Treace Medical Concepts reported a quarterly loss of $0.28 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.29, and an improvement from a loss of $0.34 per share a year ago, resulting in an earnings surprise of +3.45% [1] - The company achieved revenues of $47.39 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.79% and showing an increase from $44.46 million in the same quarter last year [2] - Treace Medical Concepts has consistently surpassed consensus EPS estimates over the last four quarters, indicating a positive trend in performance [2] 分组2 - The stock has underperformed the market, losing approximately 26.5% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $49.93 million, and for the current fiscal year, it is -$0.80 on revenues of $226.97 million [7] - The Zacks Industry Rank for Medical - Instruments is in the bottom 41% of over 250 Zacks industries, suggesting that the industry outlook may negatively impact stock performance [8]
Treace Medical Concepts (TMCI) Reports Q2 Loss, Beats Revenue Estimates